BOSTON, March 07, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), an orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a conference call and live audio webcast on Tuesday, March 14, 2017, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2016, and provide a business update.
To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international) and provide the access code 13654743. The live audio webcast will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com.
To ensure a timely connection to the call or webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



